TY - JOUR
T1 - Nanogel-based nasal vaccines for infectious and lifestyle-related diseases
AU - Azegami, Tatsuhiko
AU - Yuki, Yoshikazu
AU - Nakahashi, Rika
AU - Itoh, Hiroshi
AU - Kiyono, Hiroshi
N1 - Funding Information:
This work was supported by AMED-CREST , the Japan Agency for Medical Research and Development ; the Research on Development of New Drugs program of the Japan Agency for Medical Research and Development ; AMED-SATREPS (The Japan Agency for Medical Research and Development-Science and Technology Research Partnership for Sustainable Development); AMED-Practical Research Project for Allergic Diseases and Immunology ; MEXT KAKENHI grant number 25870715 ; the Japan Health Foundation; and the Mochida Memorial Foundation for Medical and Pharmaceutical Research .
Publisher Copyright:
© 2017
PY - 2018/6
Y1 - 2018/6
N2 - Because the mucosa is the major entry route for most pathogens, the development of mucosal vaccines is a rational approach for protecting against these undesired agents. Mucosal administration of vaccine antigen is useful for non-infectious chronic diseases as well, because of its advantages over injection routes, including comparable efficacy in the induction of systemic immune responses, less pain, and no risk of adverse events at the injection site. However, because it is difficult to effectively induce and regulate antigen-specific mucosal and systemic immune responses when antigen alone is mucosally administered, an appropriate form of mucosal delivery vehicle must be used. Antigen delivery systems involving nanogels, which act as artificial chaperones and mucosal adhesives, are a promising approach to overcoming this problem. Here, we introduce current perspectives regarding the development of nanogel-based nasal vaccines for both infectious and lifestyle-related diseases.
AB - Because the mucosa is the major entry route for most pathogens, the development of mucosal vaccines is a rational approach for protecting against these undesired agents. Mucosal administration of vaccine antigen is useful for non-infectious chronic diseases as well, because of its advantages over injection routes, including comparable efficacy in the induction of systemic immune responses, less pain, and no risk of adverse events at the injection site. However, because it is difficult to effectively induce and regulate antigen-specific mucosal and systemic immune responses when antigen alone is mucosally administered, an appropriate form of mucosal delivery vehicle must be used. Antigen delivery systems involving nanogels, which act as artificial chaperones and mucosal adhesives, are a promising approach to overcoming this problem. Here, we introduce current perspectives regarding the development of nanogel-based nasal vaccines for both infectious and lifestyle-related diseases.
KW - Hypertension
KW - Nanogel
KW - Nasal vaccine
KW - Obesity
KW - Pneumonia
UR - http://www.scopus.com/inward/record.url?scp=85032722380&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032722380&partnerID=8YFLogxK
U2 - 10.1016/j.molimm.2017.10.022
DO - 10.1016/j.molimm.2017.10.022
M3 - Review article
C2 - 29096936
AN - SCOPUS:85032722380
SN - 0161-5890
VL - 98
SP - 19
EP - 24
JO - Molecular Immunology
JF - Molecular Immunology
ER -
